EUCTR2004-001712-31-GB进行中（未招募）不适用
A study to evaluate the biological effects of RAD001 on invasive breast cancer
othian Health - University Hospitals Division0 个研究点开始时间: 2005年7月25日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Postmenopausal females, fresh tissue available from core biopsies taken at diagnosis, no evidence of metastatic disease, operable breast cancer, written informed consent from all subjects
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior therapy for breast cancer, inflammatory breast cancer, concurrent medical or psychiatric problems unrelated to breast cancer which would limit compliance, treatment with another investigational drug within 30 days or five half-lives prior to entry into the study, receiving or expected to require concurrent chemotherapy, immunotherapy, radiotherapy, chronic corticosteroid therapy or other hormonal therapy for breast cancer.
研究者
相似试验
已完成
不适用
A Phase Ib Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16*-18F-fluoro-17*-estradiol Positron Emission Tomography Imaging10006291Metastatic breast cancerNL-OMON45904Radius Pharmaceuticals, Inc.10
尚未招募
2 期
Treatment of Abnormal Vaginal Discharge by giving Vaginal Wash.CTRI/2023/09/057996Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital Thanniruhalla BMRoad Hassan
进行中（未招募）
不适用
A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET) - NDPancreatic neuroendocrine tumor (NET)MedDRA version: 6.1Level: PTClassification code 10052399EUCTR2006-006819-75-ITOVARTIS FARMA392
进行中（未招募）
不适用
A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET) - N/APancreatic neuroendocrine tumors(also called pancreatic endocrine tumors or islet cell tumors (ICT))MedDRA version: 9.1Level: LLTClassification code 10033630Term: Pancreatic islet cell neoplasm malignant NOSEUCTR2006-006819-75-FRovartis Pharma Services AG392
进行中（未招募）
1 期
A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET) - N/APancreatic neuroendocrine tumors(also called pancreatic endocrine tumors or islet cell tumors (ICT))MedDRA version: 9.1Level: LLTClassification code 10033630Term: Pancreatic islet cell neoplasm malignant NOSEUCTR2006-006819-75-SKovartis Pharma Services AG392